Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America
27 Jun 2023
License out/inPhase 2
Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million.
The companies, both of which are based in Chicago, said Tuesday that they entered into an exclusive multi-year licensing agreement to commercialize Xentria’s lead candidate, XTMAB-16, which is being tested as a treatment for a rare lung disease that commonly occurs in women and African American patients. The monoclonal antibody is set to enter a Phase II clinical trial later this year.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.